PROM1 and colorectal carcinoma: Furthermore, the concentration of 1 μg/mL 293C3-SDIE that was found to be sufficient to saturate CD133 binding and to potently induce ADCC appears easily achievable in humans, since other anti-tumor mAbs such as cetuximab and panitumumab achieve about 100-fold higher mean plasma peak levels in CRC patients upon recommended dosing [32,33].